ClinicalTrials.gg
CompletedNCT02014467Updated Oct 31, 2016Results posted

Denosumab China Phase III Study

A Phase 3 interventional study of Denosumab and Placebo in Osteoporosis, Postmenopausal, sponsored by GlaxoSmithKline. Completed at 8 sites in China. Open to female participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2016-10-31.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
486
Allocation
Randomized
Ages
60 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Enrollment
8th of 31
486 · median 278
Started
2014
with 2 others
Phase 3
17 of 31
1 open now
Registered
16th of 31
by date
Lead sponsor
3 of 31
GlaxoSmithKline

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 8th largest by enrollment, is one of 3 that started in 2014, is one of 17 in phase 3, and was the 16th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 60 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

This study is to evaluate the efficacy and safety of denosumab 60 milligrams (mg) for 12 month treatment in Chinese postmenopausal women with osteoporosis at increased risk of fracture.

Read the detailed description

The aim of this Phase III, randomized, double-blind, placebo-controlled, parallel-group study is to evaluate the efficacy and safety of denosumab (DMAb) in Chinese postmenopausal women with osteoporosis at increased risk of fracture. The study design consists of two phases: Screening and 12-month Double-Blind treatment phase. Following the Screening phase, all eligible subjects will be randomized to receive Double-Blind DMAb (60 mg) or Placebo study medication in a 3:1 ratio. DMAb 60 mg and placebo will be administered as a single subcutaneous (SC) injection at the beginning of the Double-Blind phase and at 6 months following the initial dose. All subjects will receive daily supplementation of oral elemental calcium (at least 600 mg) and vitamin D (at least 400 International Units [IU]). The primary objective is to determine the effects of DMAb compared to placebo with respect to mean percent change in BMD at the lumbar spine, as measured by dual-energy x-ray absorptiometry (DXA), from Baseline to Month 12. Secondary objectives include the evaluation between the DMAb and placebo treatment groups: change in BMD: at the lumbar spine (Month 6), total hip (Months 6 and 12), femoral neck (Months 6 and 12) and trochanter (Months 6 and 12); and serum biomarkers of bone formation and resorption (Months 6 and 12). Clinical safety of denosumab will also be assessed in this population.

03

Conditions studied

  • Osteoporosis, Postmenopausal
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is willing and able to provide written .
  • Of Chinese origin - defined as being born in China, having four ethnic Chinese grandparents.
  • Ambulatory woman between the age of 60 and 90 years, inclusive.
  • The subject has a BMD absolute value consistent with a T-score\<-2.5 and >-4.0 at either the lumbar spine or total hip.
  • All subjects must have at least one of following additional the risk factors:

history of fracture parental history of hip fracture increased bone turnover rate at screening (s-CTX >1.0 SD above the mean in healthy premenopausal women) low body weight (≤19kg/m2) elderly (age≥70y) current smoker

  • defined as >5 years postmenopausal, which can be >5 years of spontaneous amenorrhea or >5 years post surgical bilateral oophorectomy. Use follicle stimulating hormone (FSH) levels >40 mIU/mL to confirm surgical postmenopausal status, where bilateral oophorectomy status is uncertain.

Exclusion criteria

Exclusion Criteria:

  • Bone/metabolic disease:

Any metabolic bone disease, e.g., osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings.

Paget's disease Cushing's disease Hyperprolactinemia

  • Current hyperparathyroidism or hypoparathyroidism by medical record
  • Thyroid condition: Hyperthyroidism or hypothyroidism. Only subjects with hypothyroidism who are on stable thyroid hormone replacement therapy may be allowed per the following criteria:

If TSH level is below normal range, subject is not eligible for the study. If TSH level is elevated (>5.5 μIU/mL and ≤10.0 μIU/mL), serum T4 should be measured.

If serum T4 is within normal range, subject is eligible. If serum T4 is outside of normal range, subject is not eligible for the study. If TSH level is > 10.0 μIU/mL, subject is not eligible.

  • Rheumatoid arthritis
  • :

Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5years.

  • Malabsorption syndrome: malabsorption syndrome or any gastrointestinal disorders associated with malabsorption, for example Crohn's Disease and chronic pancreatitis.
  • Renal disease - severe renal impairment
  • Liver disease:

Cirrhosis of the liver Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). Chronic stable and C are acceptable if the subject otherwise meets study entry criteria (e.g., presence of hepatitis B surface antigen or positive test result within 3 months of Screening).

  • Drug or alcohol abuse: Evidence of alcohol or substance-abuse within the last 12 months which the investigator believes would interfere with understanding or completing the study.
  • Biological abnormalities:

Any disorder that compromises the ability of the subject to give written or to comply with study procedures.

Any physical or psychiatric disorder which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results.

Known to have tested positive for (HIV).

  • Vitamin D deficiency: Vitamin D deficiency (25-(OH) vitamin D level \<20 ng/mL). Vitamin D repletion will be permitted and after repletion subjects may be re-tested once for 25-(OH) vitamin D levels.
  • Oral/Dental Conditions Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw. Active dental or jaw condition which requires oral surgery. Planned invasive dental procedure. Non-healed dental or oral surgery.

Concomitant Medications:

  • Previous strontium or IV bisphosphonate: Administration of intravenous (IV) bisphosphonate, fluoride, or strontium for osteoporosis within the last 5 years.
  • Oral bisphosphonate: Oral bisphosphonate treatment for osteoporosis:

If used for ≥3 years cumulatively, subject is ineligible.

If used for >3-months but \<3 years cumulatively:

If the last dose was \<1 year before enrolment, subject is ineligible. If the last dose was ≥1 year before enrolment, subject is eligible. If used ≤3 months, cumulatively, subject is eligible.

  • Bone metabolism drugs: Administration of any of the following treatments within the last 6 weeks:

Parathyroid hormone (PTH) or PTH derivatives, e.g., teriparatide. Anabolic steroids or testosterone. Glucocorticosteroids (>5 mg prednisone equivalent per day for more than 10 days).

Systemic hormone replacement therapy. Selective estrogen receptor modulators (SERMs), e.g., raloxifene Tibolone. Calcitonin. Calcitriol or vitamin D derivatives. Other bone active drugs including anti-convulsives (except benzodiazepines) and heparin.

Chronic systemic ketoconazole, androgens, ACTH, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, gonadotropin-releasing hormone agonists.

  • drug exposure: Currently enrolled in an investigational device or drug trial(s) or it has not been at least 30 days since the last study visit in an investigational device or drug trial(s), or subject is receiving other investigational agent(s).
  • Sensitivity: Known sensitivity to mammalian cell-derived drug products.
  • to denosumab Abnormal laboratory values
  • General: Any laboratory abnormality which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results.
  • Abnormal serum calcium: current hypocalcemia or hypercalcemia. Albumin adjusted serum calcium levels must be within normal limits of the central laboratory.
  • Liver transaminases:

Serum (AST) ≥2.0 x (ULN). Serum alanine aminotransferase (ALT) ≥2.0 x ULN. Alkaline phosphatase and ≥1.5 x ULN (isolated bilirubin ≥1.5 ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%.

  • DXA measurements:

Less than two lumbar vertebrae evaluable for DXA measurements. Height, weight, or girth which may preclude accurate DXA measurements.

  • Subjects with a history of greater than 2 vertebral fractures.
  • Subjects at very high risk of fracture who must be treated with active drugs in the opinion of investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
486 participants (actual)

Study arms

  • Experimental
    Denosumab 60mg

    injection

    Drug: Denosumab · Dietary Supplement: Elemental Calcium · Dietary Supplement: Vitamin D

  • Placebo comparator
    Placebo

    injection

    Drug: Placebo · Dietary Supplement: Elemental Calcium · Dietary Supplement: Vitamin D

Interventions

  • Injection

  • DrugPlacebo

    Injection

  • Dietary supplementElemental Calcium

    Oral, at least 600 mg

  • Dietary supplementVitamin D

    Oral, at least 400 IU

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12

    Bone mineral density (BMD) is the amount of bone mineral in bone tissue. BMD scan was done using dual energy x-ray absorptiometry (DXA). It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calcuated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. The analysis was performed by Analysis of Covariance (ANCOVA) model adjusted for treatment, region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as Baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the Last Observation Carried Forward (LOCF), provided the assessment was taken on or after at least one month on-therapy.

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Percent Change From Baseline in BMD at the Lumbar Spine at Month 6

    BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

    Time frame: Baseline and Month 6

  2. Percent Change From Baseline in BMD at the Total Hip at Month 6

    BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

    Time frame: Baseline and Month 6

  3. Percent Change From Baseline in BMD at the Femoral Neck at Month 6

    BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

    Time frame: Baseline and Month 6

  4. Percent Change From Baseline in BMD at the Trochanter at Month 6

    BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

    Time frame: Baseline and Month 6

  5. Percent Change From Baseline in BMD at the Total Hip at Month 12

    BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

    Time frame: Baseline and Month 12

  6. Percent Change From Baseline in BMD at the Femoral Neck at Month 12

    BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

    Time frame: Baseline and Month 12

  7. Percent Change From Baseline in BMD at the Trochanter at Month 12

    BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

    Time frame: Baseline and Month 12

  8. Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) From Baseline to Month 6 and Month 12

    s-CTX is biomarker of bone resorption and formation. s-CTX was assessed during Screening, Month 6 and Month 12 in the Double-blind Treatment Phase. The value during Screening was considered as the Baseline value. Percent change from Baseline was assessed as the value at the indicated visit minus the Baseline value divided by the Baseline value x 100. A two-sided Wilcoxon rank sum test was used to compare percent change in s-CTX. Between group inferences is presented by p-values, Hodges-Lehmann estimates along with 95% confidence intervals.

    Time frame: Baseline, Month 6 and Month 12

  9. Percent Change in Serum Procollagen Type I N Propeptideserum (s-PINP) From Baseline to Month 6 and Month 12

    s-PINP is biomarker of bone resorption and formation. s-PINP was assessed during Screening, Month 6 and Month 12 in the Double-blind Treatment Phase. The value during Screening was considered as the Baseline value. Percent change from Baseline was assessed as the value at the indicated visit minus the Baseline value divided by the Baseline value x 100. A two-sided Wilcoxon rank sum test was used to compare percent change in serum CTX. Between group inferences is presented by p-values, Hodges-Lehmann estimates along with 95% confidence intervals.

    Time frame: Baseline, Month 6, Month 12

  10. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Month 1, Month 3, Month 6, and Month 12

    Baseline value was obtained at Randomization (Visit 3). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Change from Baseline in SBP and DBP was assessed at Baseline, Month 1, Month 3, Month 6, and Month 12.

    Time frame: Baseline, Month 1, Month 3, Month 6 and Month 12

  11. Change From Baseline in Heart Rate at Month 1, Month 3, Month 6, and Month 12

    Baseline value was obtained at Randomization (Visit 3). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Change from Baseline in heart rate was assessed at Baseline, Month 1, Month 3, Month 6 and Month 12.

    Time frame: Baseline, Month 1, Month 3, Month 6 and Month 12

  12. Change From Baseline in Alanine Amino Transferase, Alkaline Phosphatase, Aspartate Amino Transferase, and Gamma Glutamyl Transferase at Month 1, Month 6 and Month 12

    Baseline values were obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Alanine amino transferase, alkaline phosphatase, aspartate amino transferase, and gamma glutamyl transferase were assessed at Baseline, Month 1, Month 6 and Month 12.

    Time frame: Baseline, Month 1, Month 6, and Month 12

  13. Change From Baseline in Creatine Kinase, Lactate Dehydrogenase at Month 6 and Month 12.

    Baseline values was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Creatine kinase and lactate dehydrogenase were assessed at Baseline, Month 6 and Month 12.

    Time frame: Baseline, Month 6 and Month 12

  14. Change From Baseline in Albumin at Month 1, Month 6 and Month 12.

    Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Albumin was assessed at Baseline, Month 1, Month 6 and Month 12.

    Time frame: Baseline, Month 1, Month 6 and Month 12.

  15. Change From Baseline in Globulin at Month 6 and Month 12.

    Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at indicated visit minus the Baseline value. Blood samples were collected for measurement. Globulin was assessed at Baseline, Month 6 and Month 12.

    Time frame: Baseline, Month 6 and Month 12

  16. Change From Baseline in Hemoglobin and Total Protein at Month 6 and Month 12.

    Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at indicated visit minus the Baseline value. Blood samples were collected for measurement. Hemoglobin and total protein were assessed at Baseline, Month 6 and Month 12.

    Time frame: Baseline, Month 6 and Month 12

  17. Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils-total Absolute Neutrophil Count (ANC), White Blood Cell Count at Month 6 and Month 12.

    Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Basophils, eosinophils, lymphocytes, monocytes, platelet count, total neutrophils-total ANC and white blood cell count were assessed at Baseline, Month 6 and Month 12.

    Time frame: Baseline, Month 6 and Month 12

  18. Change From Baseline in Calcium (Corrected), Calcium at Month 1, Month 6 and Month 12.

    Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Calcium (corrected) and calcium were assessed at Baseline, Month 1, Month 6 and Month 12.

    Time frame: Baseline, Month 1, Month 6 and Month 12.

  19. Change From Baseline in Chloride, Cholesterol, Glucose, Magnesium, Inorganic Phosphorous, Potassium, Sodium, Triglycerides, Urea/Blood Urea Nitrogen (BUN) at Month 6 and Month 12.

    Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Chloride, cholesterol, glucose, magnesium, inorganic phosphorous, potassium, sodium, triglycerides and urea/BUN were assessed at Baseline, Month 6 and Month 12.

    Time frame: Baseline, Month 6 and Month 12

  20. Change From Baseline in Direct Bilirubin, Total Bilirubin at Month 1, Month 6 and Month 12.

    Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Direct bilirubin and total bilirubin were assessed at Baseline, Month 1, Month 6 and Month 12.

    Time frame: Baseline, Month 1, Month 6 and Month 12

  21. Change From Baseline in Creatinine and Uric Acid at Month 6 and Month 12

    Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Creatinine and uric acid were assessed at Baseline, Month 6 and Month 12.

    Time frame: Baseline, Month 6 and Month 12

  22. Change From Baseline in Hematocrit at Month 6 and Month 12.

    Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Hematocrit was assessed at Baseline, Month 6 and Month 12.

    Time frame: Baseline, Month 6 and Month 12.

  23. Change From Baseline in Mean Corpuscle Hemoglobin at Month 6 and Month 12.

    Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Mean corpuscle hemoglobin was assessed at Baseline, Month 6 and Month 12.

    Time frame: Baseline, Month 6 and Month 12.

  24. Change From Baseline in Mean Corpuscle Volume at Month 6 and Month 12.

    Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Mean corpuscle volume was assessed at Baseline, Month 6 and Month 12.

    Time frame: Baseline, Month 6 and Month 12

  25. Change From Baseline in Red Blood Cell Count at Month 6 and Month 12

    Baseline value was obtained at screening (visit 2). If missing, the most recent non-missing value was used. Change in baseline value was assessed as: Value at Indicated visit minus Baseline value. Blood samples were collected for measurement. Red blood cell count was assessed at Baseline, Month 6 and Month 12.

    Time frame: Baseline, Month 6 and Month 12

  26. Number of Participants With Confirmed Anti-denosumab Antibody Formation at Baseline and Month 12

    Anti-denosumab antibody formation was assessed at Baseline (Visit 3) and Month 12. Binding antibody and neutralizing antibody assays were used to assess number of participants with anti-denosumab antibody.

    Time frame: Baseline and Month 12

  27. Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (Non-fatal Serious Adverse Events and Fatal Serious Adverse Events)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or other events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the outcome listed above, liver injury and impaired liver function and grade 4 laboratory abnormalities. Number of participants with any AEs, serious non-fatal AEs, serious fatal AEs have been presented.

    Time frame: From start of IP through the Study Phase (6 months post-dose) (assessed up to 12 months)

07

Results

Posted Oct 31, 2016

Participant flow

The study design consists of two phases: Screening Phase and 12-month Double-blind Treatment Phase. The Screening Phase was to last up to a maximum of 2.5 months, which was followed by a 12-month Double-blind Treatment Phase. The total participation time in the study was approximately 14.5 months.

Participant flow — Overall Study
MilestoneDenosumab 60 mgPlacebo
Started365119
Completed340112
Not completed257
Withdrew: Adverse event40
Withdrew: Protocol violation30
Withdrew: Physician decision23
Withdrew: Withdrawal by subject164

Outcome measures

PrimaryPercent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12

Bone mineral density (BMD) is the amount of bone mineral in bone tissue. BMD scan was done using dual energy x-ray absorptiometry (DXA). It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calcuated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. The analysis was performed by Analysis of Covariance (ANCOVA) model adjusted for treatment, region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as Baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the Last Observation Carried Forward (LOCF), provided the assessment was taken on or after at least one month on-therapy.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · Percentage change
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12
Percentage changeDenosumab 60 mgPlacebo
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 125.22 ± 0.2740.79 ± 0.391
Statistical analysis
  • Denosumab 60 mg vs Placebo · ANCOVA · p = <0.0001 · Mean difference (net): 4.42 · 95% CI 3.67 to 5.18
  • Denosumab 60 mg vs Placebo · ANCOVA · p = 0.7495 (Treatment By Region Interaction: Based on ANCOVA, Percent change from Baseline = Baseline + treatment + region + treatment by region)
SecondaryPercent Change From Baseline in BMD at the Lumbar Spine at Month 6

BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · Percentage change
Percent Change From Baseline in BMD at the Lumbar Spine at Month 6
Percentage changeDenosumab 60 mgPlacebo
Percent Change From Baseline in BMD at the Lumbar Spine at Month 63.77 ± 0.2730.57 ± 0.390
Statistical analysis
  • Denosumab 60 mg vs Placebo · ANCOVA · p = <0.0001 · Mean difference (net): 3.21 · 95% CI 2.45 to 3.96
  • Denosumab 60 mg vs Placebo · ANCOVA · p = 0.9029 (Treatment By Region Interaction: Based on ANCOVA, Percent change from Baseline = Baseline + treatment + region + treatment by region)
SecondaryPercent Change From Baseline in BMD at the Total Hip at Month 6

BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · Percentage change
Percent Change From Baseline in BMD at the Total Hip at Month 6
Percentage changeDenosumab 60 mgPlacebo
Percent Change From Baseline in BMD at the Total Hip at Month 62.36 ± 0.1930.11 ± 0.279
Statistical analysis
  • Denosumab 60 mg vs Placebo · ANCOVA · p = <0.0001 · Mean difference (net): 2.26 · 95% CI 1.72 to 2.80
  • Denosumab 60 mg vs Placebo · ANCOVA · p = 0.1070 (Treatment By Region Interaction: Based on ANCOVA, Percent change from Baseline = Baseline + treatment + region + treatment by region)
SecondaryPercent Change From Baseline in BMD at the Femoral Neck at Month 6

BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · Percentage change
Percent Change From Baseline in BMD at the Femoral Neck at Month 6
Percentage changeDenosumab 60 mgPlacebo
Percent Change From Baseline in BMD at the Femoral Neck at Month 61.91 ± 0.2190.32 ± 0.315
Statistical analysis
  • Denosumab 60 mg vs Placebo · ANCOVA · p = <0.0001 · Mean difference (net): 1.59 · 95% CI 0.98 to 2.20
  • Denosumab 60 mg vs Placebo · ANCOVA · p = 0.4369 (Treatment By Region Interaction: Based on ANCOVA, Percent change from Baseline = Baseline + treatment + region + treatment by region)
SecondaryPercent Change From Baseline in BMD at the Trochanter at Month 6

BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · Percentage change
Percent Change From Baseline in BMD at the Trochanter at Month 6
Percentage changeDenosumab 60 mgPlacebo
Percent Change From Baseline in BMD at the Trochanter at Month 62.76 ± 0.344-0.59 ± 0.498
Statistical analysis
  • Denosumab 60 mg vs Placebo · ANCOVA · p = <0.0001 · Mean difference (net): 3.36 · 95% CI 2.39 to 4.32
  • Denosumab 60 mg vs Placebo · ANCOVA · p = 0.6082 (Treatment By Region Interaction: Based on ANCOVA, Percent change from Baseline = Baseline + treatment + region + treatment by region)
SecondaryPercent Change From Baseline in BMD at the Total Hip at Month 12

BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · Percentage change
Percent Change From Baseline in BMD at the Total Hip at Month 12
Percentage changeDenosumab 60 mgPlacebo
Percent Change From Baseline in BMD at the Total Hip at Month 123.03 ± 0.202-0.28 ± 0.293
Statistical analysis
  • Denosumab 60 mg vs Placebo · ANCOVA · p = <0.0001 · Mean difference (net): 3.31 · 95% CI 2.74 to 3.88
  • Denosumab 60 mg vs Placebo · ANCOVA · p = 0.3513 (Treatment By Region Interaction: Based on ANCOVA, Percent change from Baseline = Baseline + treatment + region + treatment by region)
SecondaryPercent Change From Baseline in BMD at the Femoral Neck at Month 12

BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · Percentage change
Percent Change From Baseline in BMD at the Femoral Neck at Month 12
Percentage changeDenosumab 60 mgPlacebo
Percent Change From Baseline in BMD at the Femoral Neck at Month 122.77 ± 0.2330.16 ± 0.337
Statistical analysis
  • Denosumab 60 mg vs Placebo · ANCOVA · p = <0.0001 · Mean difference (net): 2.62 · 95% CI 1.96 to 3.27
  • Denosumab 60 mg vs Placebo · ANCOVA · p = 0.5410 (Treatment By Region Interaction: Based on ANCOVA, Percent change from Baseline = Baseline + treatment + region + treatment by region)
SecondaryPercent Change From Baseline in BMD at the Trochanter at Month 12

BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · Percentage change
Percent Change From Baseline in BMD at the Trochanter at Month 12
Percentage changeDenosumab 60 mgPlacebo
Percent Change From Baseline in BMD at the Trochanter at Month 123.88 ± 0.356-0.83 ± 0.517
Statistical analysis
  • Denosumab 60 mg vs Placebo · ANCOVA · p = <0.0001 · Mean difference (net): 4.72 · 95% CI 3.71 to 5.72
  • Denosumab 60 mg vs Placebo · ANCOVA · p = 0.3957 (Treatment By Region Interaction: Based on ANCOVA, Percent change from Baseline = Baseline + treatment + region + treatment by region)
SecondaryPercent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) From Baseline to Month 6 and Month 12

s-CTX is biomarker of bone resorption and formation. s-CTX was assessed during Screening, Month 6 and Month 12 in the Double-blind Treatment Phase. The value during Screening was considered as the Baseline value. Percent change from Baseline was assessed as the value at the indicated visit minus the Baseline value divided by the Baseline value x 100. A two-sided Wilcoxon rank sum test was used to compare percent change in s-CTX. Between group inferences is presented by p-values, Hodges-Lehmann estimates along with 95% confidence intervals.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Median · Percentage change
Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) From Baseline to Month 6 and Month 12
Percentage changeDenosumab 60 mgPlacebo
s-CTX, Month 6, n=353, 117-79.20 (-86.80 to -66.45)-19.35 (-35.97 to -2.74)
s-CTX, Month 12, n=335, 108-64.51 (-77.29 to -38.52)-5.94 (-29.52 to 16.67)
Statistical analysis
  • Denosumab 60 mg vs Placebo · Wilcoxon Rank Sum test · p = <0.0001 (Two-Sided, Wilcoxon t Approximation) · Hodges lehmann estimate of difference: -56.92 · 95% CI -61.38 to -52.65s-CTX at Month 6
  • Denosumab 60 mg vs Placebo · Wilcoxon Rank Sum test · p = <0.0001 (Two-Sided, Wilcoxon t Approximation) · Hodges lehmann estimate of difference: -52.56 · 95% CI -59.38 to -46.17s-CTX at Month 12
SecondaryPercent Change in Serum Procollagen Type I N Propeptideserum (s-PINP) From Baseline to Month 6 and Month 12

s-PINP is biomarker of bone resorption and formation. s-PINP was assessed during Screening, Month 6 and Month 12 in the Double-blind Treatment Phase. The value during Screening was considered as the Baseline value. Percent change from Baseline was assessed as the value at the indicated visit minus the Baseline value divided by the Baseline value x 100. A two-sided Wilcoxon rank sum test was used to compare percent change in serum CTX. Between group inferences is presented by p-values, Hodges-Lehmann estimates along with 95% confidence intervals.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Median · Percentage change
Percent Change in Serum Procollagen Type I N Propeptideserum (s-PINP) From Baseline to Month 6 and Month 12
Percentage changeDenosumab 60 mgPlacebo
s-PINP, Month 6, n=352, 117-73.12 (-81.03 to -62.81)-12.37 (-29.58 to 4.37)
s-PINP, Month 12, n=335, 108-66.14 (-76.04 to -50.75)-14.83 (-27.84 to 11.26)
Statistical analysis
  • Denosumab 60 mg vs Placebo · Wilcoxon Rank Sum test · p = <0.0001 (Two-Sided, Wilcoxon t Approximation) · Hodges lehmann estimate of difference: -56.94 · 95% CI -61.60 to -52.70s-PINP at Month 6
  • Denosumab 60 mg vs Placebo · Wilcoxon Rank Sum test · p = <0.0001 (Two-Sided, Wilcoxon t Approximation) · Hodges lehmann estimate of difference: -51.21 · 95% CI -56.26 to -45.91s-PINP at Month 12
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Month 1, Month 3, Month 6, and Month 12

Baseline value was obtained at Randomization (Visit 3). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Change from Baseline in SBP and DBP was assessed at Baseline, Month 1, Month 3, Month 6, and Month 12.

Time frame:
Baseline, Month 1, Month 3, Month 6 and Month 12
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Month 1, Month 3, Month 6, and Month 12
Millimeters of mercury (mmHg)Denosumab 60 mgPlacebo
SBP, Month 1, n = 365, 117-1.8 ± 11.01-1.3 ± 11.89
SBP, Month 3, n = 362, 117-3.4 ± 12.62-0.5 ± 12.16
SBP, Month 6, n = 350, 1140.1 ± 12.761.5 ± 13.25
SBP, Month 12, n = 342, 110-0.5 ± 11.83-0.1 ± 11.69
DBP, Month 1, n = 365, 1170.0 ± 6.950.6 ± 7.58
DBP, Month 3, n = 362, 117-1.5 ± 7.700.2 ± 6.50
DBP, Month 6, n = 350, 114-0.3 ± 7.671.1 ± 8.34
DBP, Month 12, n = 342, 1100.2 ± 7.631.2 ± 7.75
SecondaryChange From Baseline in Heart Rate at Month 1, Month 3, Month 6, and Month 12

Baseline value was obtained at Randomization (Visit 3). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Change from Baseline in heart rate was assessed at Baseline, Month 1, Month 3, Month 6 and Month 12.

Time frame:
Baseline, Month 1, Month 3, Month 6 and Month 12
Reported as:
Mean · Beats per minute
Change From Baseline in Heart Rate at Month 1, Month 3, Month 6, and Month 12
Beats per minuteDenosumab 60 mgPlacebo
Heart Rate, Month 1, n = 365, 117-0.8 ± 6.88-2.1 ± 7.51
Heart Rate, Month 3, n = 362, 1171.2 ± 10.280.2 ± 9.08
Heart Rate, Month 6, n = 350, 114-0.4 ± 8.23-1.3 ± 9.01
Heart Rate, Month 12, n = 342, 110-0.9 ± 7.550.1 ± 10.48
SecondaryChange From Baseline in Alanine Amino Transferase, Alkaline Phosphatase, Aspartate Amino Transferase, and Gamma Glutamyl Transferase at Month 1, Month 6 and Month 12

Baseline values were obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Alanine amino transferase, alkaline phosphatase, aspartate amino transferase, and gamma glutamyl transferase were assessed at Baseline, Month 1, Month 6 and Month 12.

Time frame:
Baseline, Month 1, Month 6, and Month 12
Reported as:
Mean · International unit per liter (IU/L)
Change From Baseline in Alanine Amino Transferase, Alkaline Phosphatase, Aspartate Amino Transferase, and Gamma Glutamyl Transferase at Month 1, Month 6 and Month 12
International unit per liter (IU/L)Denosumab 60 mgPlacebo
Alanine Amino Transferase, Month 1, n = 365, 1170.2 ± 6.27-0.1 ± 5.91
Alanine Amino Transferase, Month 6, n = 350, 1141.9 ± 9.000.7 ± 7.19
Alanine Amino Transferase, Month 12, n = 340, 1091.5 ± 12.490.2 ± 8.45
Alkaline Phosphatase, Month 1, n = 365, 117-3.3 ± 11.00-3.2 ± 10.03
Alkaline Phosphatase, Month 6, n = 350, 114-21.0 ± 17.20-1.2 ± 11.43
Alkaline Phosphatase, Month 12, n = 340, 109-23.4 ± 17.36-5.3 ± 11.06
Aspartate Amino Transferase, Month 1, n = 365, 117-0.1 ± 4.34-0.4 ± 4.41
Aspartate Amino Transferase, Month 6, n = 350, 1141.2 ± 7.840.2 ± 5.28
Aspartate Amino Transferase,Month 12, n = 340, 1090.1 ± 7.41-0.8 ± 5.94
Gamma Glutamyl Transferase, Month 1, n = 365, 1170.2 ± 11.52-0.6 ± 5.82
Gamma Glutamyl Transferase, Month 6, n = 350, 1140.1 ± 11.22-0.1 ± 6.44
Gamma Glutamyl Transferase, Month 12, n = 340, 109-0.9 ± 9.960.3 ± 10.09
SecondaryChange From Baseline in Creatine Kinase, Lactate Dehydrogenase at Month 6 and Month 12.

Baseline values was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Creatine kinase and lactate dehydrogenase were assessed at Baseline, Month 6 and Month 12.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · International unit per liter (IU/L)
Change From Baseline in Creatine Kinase, Lactate Dehydrogenase at Month 6 and Month 12.
International unit per liter (IU/L)Denosumab 60 mgPlacebo
Creatine Kinase, Month 6, n = 350, 114-3.7 ± 43.41-3.7 ± 31.64
Creatine Kinase, Month 12, n = 340, 109-2.6 ± 53.83-0.3 ± 38.58
Lactate Dehydrogenase, Month 6, n = 350, 114-3.4 ± 19.62-5.6 ± 19.60
Lactate Dehydrogenase, Month 12, n = 340, 109-2.2 ± 18.50-4.0 ± 23.16
SecondaryChange From Baseline in Albumin at Month 1, Month 6 and Month 12.

Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Albumin was assessed at Baseline, Month 1, Month 6 and Month 12.

Time frame:
Baseline, Month 1, Month 6 and Month 12.
Reported as:
Mean · Gram per liter (G/L)
Change From Baseline in Albumin at Month 1, Month 6 and Month 12.
Gram per liter (G/L)Denosumab 60 mgPlacebo
Albumin, Month 1, n = 365, 117-0.6 ± 1.93-0.7 ± 1.75
Albumin, Month 6, n = 350, 1140.7 ± 1.960.5 ± 2.09
Albumin, Month 12, n = 340, 1090.2 ± 1.820.1 ± 2.11
SecondaryChange From Baseline in Globulin at Month 6 and Month 12.

Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at indicated visit minus the Baseline value. Blood samples were collected for measurement. Globulin was assessed at Baseline, Month 6 and Month 12.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · Grams per liter (G/L)
Change From Baseline in Globulin at Month 6 and Month 12.
Grams per liter (G/L)Denosumab 60 mgPlacebo
Globulin, Month 6, n = 350, 114-0.3 ± 2.29-0.2 ± 2.35
Globulin, Month 12, n = 340, 109-0.5 ± 2.57-0.4 ± 2.78
SecondaryChange From Baseline in Hemoglobin and Total Protein at Month 6 and Month 12.

Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at indicated visit minus the Baseline value. Blood samples were collected for measurement. Hemoglobin and total protein were assessed at Baseline, Month 6 and Month 12.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · Grams per liter (G/L)
Change From Baseline in Hemoglobin and Total Protein at Month 6 and Month 12.
Grams per liter (G/L)Denosumab 60 mgPlacebo
Hemoglobin, Month 6, n = 346, 1132.3 ± 5.331.9 ± 5.54
Hemoglobin, Month 12, n = 339, 1090.2 ± 6.120.7 ± 6.52
Total Protein, Month 6, n = 350, 1140.4 ± 3.300.3 ± 3.34
Total Protein, Month 12, n = 340, 109-0.2 ± 3.57-0.3 ± 3.60
SecondaryChange From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils-total Absolute Neutrophil Count (ANC), White Blood Cell Count at Month 6 and Month 12.

Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Basophils, eosinophils, lymphocytes, monocytes, platelet count, total neutrophils-total ANC and white blood cell count were assessed at Baseline, Month 6 and Month 12.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · Giga per liter (GI/L)
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils-total Absolute Neutrophil Count (ANC), White Blood Cell Count at Month 6 and Month 12.
Giga per liter (GI/L)Denosumab 60 mgPlacebo
Basophils, Month 6, n = 346, 113-0.002 ± 0.0180-0.001 ± 0.0180
Basophils, Month 12, n = 339, 109-0.001 ± 0.0160-0.003 ± 0.0183
Eosinophils, Month 6, n = 346, 1130.025 ± 0.14020.013 ± 0.1240
Eosinophils, Month 12, n = 339, 109-0.001 ± 0.15300.006 ± 0.1382
Lymphocytes, Month 6, n = 346, 1130.011 ± 0.3658-0.020 ± 0.3513
Lymphocytes, Month 12, n = 339, 109-0.064 ± 0.3689-0.082 ± 0.3584
Monocytes, Month 6, n = 346, 1130.042 ± 0.09990.035 ± 0.0868
Monocytes, Month 12, n = 339, 109-0.007 ± 0.1002-0.004 ± 0.0800
Platelet count, Month 6, n = 345, 1133.0 ± 30.49-0.1 ± 24.08
Platelet count, Month 12, n = 337, 109-6.8 ± 26.66-3.6 ± 30.82
Total ANC, Month 6, n = 346, 1130.153 ± 1.0436-0.002 ± 0.8814
Total ANC, Month 12, n = 339, 109-0.071 ± 0.9412-0.119 ± 0.9691
White Blood Cell count, Month 6, n = 346, 1130.23 ± 1.1660.02 ± 1.036
White Blood Cell count, Month 12, n = 339, 109-0.14 ± 1.083-0.20 ± 1.164
SecondaryChange From Baseline in Calcium (Corrected), Calcium at Month 1, Month 6 and Month 12.

Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Calcium (corrected) and calcium were assessed at Baseline, Month 1, Month 6 and Month 12.

Time frame:
Baseline, Month 1, Month 6 and Month 12.
Reported as:
Mean · Millimoles per liter (mmol/L)
Change From Baseline in Calcium (Corrected), Calcium at Month 1, Month 6 and Month 12.
Millimoles per liter (mmol/L)Denosumab 60 mgPlacebo
Calcium (corrected), Month 1, n = 365, 117-0.063 ± 0.07400.000 ± 0.0505
Calcium (corrected), Month 6, n = 350, 114-0.020 ± 0.0704-0.001 ± 0.0537
Calcium (corrected), Month 12, n = 340, 109-0.002 ± 0.0680-0.001 ± 0.0488
Calcium, Month 1, n = 365, 117-0.074 ± 0.0906-0.014 ± 0.0614
Calcium, Month 6, n = 350, 114-0.006 ± 0.08090.009 ± 0.0703
Calcium, Month 12, n = 340, 1090.002 ± 0.08070.001 ± 0.0648
SecondaryChange From Baseline in Chloride, Cholesterol, Glucose, Magnesium, Inorganic Phosphorous, Potassium, Sodium, Triglycerides, Urea/Blood Urea Nitrogen (BUN) at Month 6 and Month 12.

Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Chloride, cholesterol, glucose, magnesium, inorganic phosphorous, potassium, sodium, triglycerides and urea/BUN were assessed at Baseline, Month 6 and Month 12.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · Millimoles per liter (mmol/L)
Change From Baseline in Chloride, Cholesterol, Glucose, Magnesium, Inorganic Phosphorous, Potassium, Sodium, Triglycerides, Urea/Blood Urea Nitrogen (BUN) at Month 6 and Month 12.
Millimoles per liter (mmol/L)Denosumab 60 mgPlacebo
Chloride, Month 6, n = 350, 114-0.9 ± 2.48-0.7 ± 2.37
Chloride, Month 12, n = 340, 1090.4 ± 2.170.6 ± 2.34
Cholesterol, Month 6, n = 350, 1140.039 ± 0.76260.057 ± 0.7837
Cholesterol, Month 12, n = 340, 1090.047 ± 0.89090.058 ± 0.7889
Glucose, Month 6, n = 350, 1140.12 ± 0.8820.04 ± 1.052
Glucose, Month 12, n = 340, 1090.16 ± 0.124-0.07 ± 0.752
Magnesium, Month 6, n = 350, 1140.003 ± 0.0523-0.002 ± 0.0547
Magnesium, Month 12, n = 340, 1090.013 ± 0.04850.012 ± 0.0572
Phosphorus, inorganic, Month 6, n = 350, 114-0.082 ± 0.1440-0.030 ± 0.1353
Phosphorus, inorganic, Month 12, n = 340, 109-0.063 ± 0.1520-0.028 ± 0.1304
Potassium, Month 6, n = 350, 1140.00 ± 0.3280.02 ± 0.294
Potassium, Month 12, n = 340, 1090.01 ± 0.300-0.01 ± 0.294
Sodium, Month 6, n = 350, 114-0.8 ± 1.94-0.4 ± 2.24
Sodium, Month 12, n = 340, 109-1.3 ± 1.93-0.7 ± 1.76
Triglycerides, Month 6, n = 350, 114-0.082 ± 0.7604-0.000 ± 0.6753
Triglycerides, Month 12, n = 340, 109-0.014 ± 0.9367-0.029 ± 0.7489
Urea/BUN, Month 6, n = 350, 114-0.18 ± 1.045-0.35 ± 1.288
Urea/BUN, Month 12, n = 340, 1090.04 ± 1.1240.01 ± 1.466
SecondaryChange From Baseline in Direct Bilirubin, Total Bilirubin at Month 1, Month 6 and Month 12.

Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Direct bilirubin and total bilirubin were assessed at Baseline, Month 1, Month 6 and Month 12.

Time frame:
Baseline, Month 1, Month 6 and Month 12
Reported as:
Mean · Micromoles per liter (UMOL/L)
Change From Baseline in Direct Bilirubin, Total Bilirubin at Month 1, Month 6 and Month 12.
Micromoles per liter (UMOL/L)Denosumab 60 mgPlacebo
Direct Bilirubin, Month 1, n = 365, 117-0.1 ± 0.670.1 ± 0.52
Direct Bilirubin, Month 6, n = 350, 1140.0 ± 0.720.1 ± 0.66
Direct Bilirubin, Month 12, n = 340, 1090.1 ± 0.670.2 ± 0.68
Total Bilirubin, Month 1, n = 365, 117-0.3 ± 2.830.2 ± 2.61
Total Bilirubin, Month 6, n = 350, 1140.1 ± 2.910.2 ± 2.66
Total Bilirubin, Month 12, n = 340, 1090.3 ± 2.980.2 ± 2.80
SecondaryChange From Baseline in Creatinine and Uric Acid at Month 6 and Month 12

Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Creatinine and uric acid were assessed at Baseline, Month 6 and Month 12.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · Micromoles per liter (UMOL/L)
Change From Baseline in Creatinine and Uric Acid at Month 6 and Month 12
Micromoles per liter (UMOL/L)Denosumab 60 mgPlacebo
Creatinine, Month 6, n = 350, 114-0.47 ± 5.067-0.90 ± 5.611
Creatinine, Month 12, n = 340, 109-0.18 ± 5.116-0.30 ± 6.185
Uric acid, Month 6, n = 350, 114-8.9 ± 48.33-8.9 ± 48.58
Uric acid, Month 12, n = 340, 109-6.7 ± 49.84-2.7 ± 44.85
SecondaryChange From Baseline in Hematocrit at Month 6 and Month 12.

Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Hematocrit was assessed at Baseline, Month 6 and Month 12.

Time frame:
Baseline, Month 6 and Month 12.
Reported as:
Mean · Ratio
Change From Baseline in Hematocrit at Month 6 and Month 12.
RatioDenosumab 60 mgPlacebo
Hematocrit, Month 6, n = 346, 1130.0024 ± 0.016120.0012 ± 0.01662
Hematocrit, Month 12, n = 339, 1090.0064 ± 0.018840.0079 ± 0.01926
SecondaryChange From Baseline in Mean Corpuscle Hemoglobin at Month 6 and Month 12.

Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Mean corpuscle hemoglobin was assessed at Baseline, Month 6 and Month 12.

Time frame:
Baseline, Month 6 and Month 12.
Reported as:
Mean · Picograms (PG)
Change From Baseline in Mean Corpuscle Hemoglobin at Month 6 and Month 12.
Picograms (PG)Denosumab 60 mgPlacebo
Mean Corpuscle Hemoglobin, Month 6, n = 346, 1130.22 ± 0.5990.18 ± 0.561
Mean Corpuscle Hemoglobin, Month 12, n = 339, 109-0.31 ± 0.691-0.38 ± 0.600
SecondaryChange From Baseline in Mean Corpuscle Volume at Month 6 and Month 12.

Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Mean corpuscle volume was assessed at Baseline, Month 6 and Month 12.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · Femtoliter (FL)
Change From Baseline in Mean Corpuscle Volume at Month 6 and Month 12.
Femtoliter (FL)Denosumab 60 mgPlacebo
Mean Corpuscle Volume, Month 6, n = 346, 113-0.4 ± 1.77-0.5 ± 2.17
Mean Corpuscle Volume, Month 12, n = 339, 1090.4 ± 2.010.3 ± 1.77
SecondaryChange From Baseline in Red Blood Cell Count at Month 6 and Month 12

Baseline value was obtained at screening (visit 2). If missing, the most recent non-missing value was used. Change in baseline value was assessed as: Value at Indicated visit minus Baseline value. Blood samples were collected for measurement. Red blood cell count was assessed at Baseline, Month 6 and Month 12.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · Trillion cells per liter (TI/L)
Change From Baseline in Red Blood Cell Count at Month 6 and Month 12
Trillion cells per liter (TI/L)Denosumab 60 mgPlacebo
Red Blood Cell count, Month 6, n = 346, 1130.04 ± 0.1800.04 ± 0.170
Red Blood Cell count, Month 12, n = 339, 1090.05 ± 0.2030.07 ± 0.200
SecondaryNumber of Participants With Confirmed Anti-denosumab Antibody Formation at Baseline and Month 12

Anti-denosumab antibody formation was assessed at Baseline (Visit 3) and Month 12. Binding antibody and neutralizing antibody assays were used to assess number of participants with anti-denosumab antibody.

Time frame:
Baseline and Month 12
Reported as:
Number · Participants
Number of Participants With Confirmed Anti-denosumab Antibody Formation at Baseline and Month 12
ParticipantsDenosumab 60 mgPlacebo
Binding antibody detection, Baseline, n = 15, 300
Binding antibody detection, Month 12, n = 29, 310
Neutralising antibody detection,Month 12, n = 1,000
SecondaryNumber of Participants With Any Adverse Events (AEs), Serious Adverse Events (Non-fatal Serious Adverse Events and Fatal Serious Adverse Events)

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or other events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the outcome listed above, liver injury and impaired liver function and grade 4 laboratory abnormalities. Number of participants with any AEs, serious non-fatal AEs, serious fatal AEs have been presented.

Time frame:
From start of IP through the Study Phase (6 months post-dose) (assessed up to 12 months)
Reported as:
Number · Participants
Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (Non-fatal Serious Adverse Events and Fatal Serious Adverse Events)
ParticipantsDenosumab 60 mgPlacebo
Any AEs17463
Any Serious Non-Fatal AEs93
Any Serious Fatal AEs20

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of IP through the Study Phase (6 months post-dose) (assessed up to 12 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab 60mg—11/367 (3%)43/367 (11.7%)
Placebo—3/117 (2.6%)24/117 (20.5%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventDenosumab 60mgPlacebo
Any eventCardiac disorders1/3672/117
Any eventInjury, poisoning and procedural complications3/3671/117
Humerus fractureInjury, poisoning and procedural complications0/3671/117
Angina unstableCardiac disorders0/3671/117
ArrhythmiaCardiac disorders0/3671/117
Arteriosclerosis coronary arteryCardiac disorders0/3671/117
Myocardial infarctionCardiac disorders0/3671/117
Any eventNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/3670/117
Femoral neck fractureInjury, poisoning and procedural complications2/3670/117
Any eventInfections and infestations2/3670/117
Most frequent other events
Most frequent other events
EventDenosumab 60mgPlacebo
Blood cholesterol increasedInvestigations19/36711/117
ArthralgiaInvestigations24/3679/117
Bone density decreasedInvestigations2/3676/117

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Denosumab 60 mgPlaceboTotal
Mean68.9 ± 6.1069.6 ± 5.7569.0 ± 6.02
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab 60 mgPlaceboTotal
Female365119484
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Denosumab 60 mgPlaceboTotal
Asian - East Asian Heritage365119484
08

Study locations

8 sites
  • GSK Investigational Site
    Chengdu, Sichuan 610041, China
  • GSK Investigational Site
    Chengdu, Sichuan 610072, China
  • GSK Investigational Site
    Beijing, 100035, China
  • GSK Investigational Site
    Beijing, 100050, China
  • GSK Investigational Site
    Beijing, 100730, China
  • GSK Investigational Site
    Chengdu, 610083, China
  • GSK Investigational Site
    Shanghai, 200040, China
  • GSK Investigational Site
    Shanghai, 200233, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2013
First posted
Dec 18, 2013
Start
Jan 2014
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Oct 31, 2016
Last update
Oct 31, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02014467
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 18, 2013
Start date
Jan 2014
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Oct 31, 2016
Last update
Oct 31, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion